Alcyone Therapeutics Inc. is a pioneering company in the biotechnology and health and wellness industries, focusing on next-generation intra-CSF (cerebrospinal fluid) CNS precision gene-based therapies. Established in 2010, the company's mission is to develop therapeutic and precision delivery solutions to bring impactful change to people living with neurological conditions and their support network.
The most recent investment in Alcyone Therapeutics Inc. was a $23.00M Venture Round funded on 09 June 2021. The investment was led by RTW Investments.
Alcyone Therapeutics Inc. is at the forefront of advancing treatment options for neurological conditions through innovative gene-based therapies, and the recent investment underscores investor confidence in the company's vision and potential impact on the healthcare industry.